A modular topical patch system may include two or more topical patches that share a commonality to allow them to be affixed adjacent, parallel or in close proximity to one another on skin of a user to facilitate pain relief. The commonality may be a common dimension, a common angle, a complementary angle, a common shape and/or a complementary shape.
An improved immediate release solid dosage form of naproxen with a certain particle size distribution for the intragranular portion, and a certain particle size distribution for the carbonate portion that allows naproxen to remain in solution and achieves fast dissolution and fast absorption of naproxen. The invention provides a naproxen dosage form that when administered to a human in a fasted state provides an average blood plasma naproxen concentration of at least 15-20 μg/ml in 10 minutes or less. The invention also provides a naproxen dosage form that when administered to a human in a fed state provides an average blood plasma naproxen concentration of at least 15-20 μg/ml in 50 minutes or less.
The present invention relates to a single layer chewable tablet comprising cetirizine, an optical isomer, or a pharmaceutically active salt thereof and at least one polyol. The present invention also relates to a method of alleviating a sign or symptom of allergy by orally administering the same single layer chewable tablet.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Concentrated compositions, methods of using concentrated compositions, kits including concentrated compositions, and diluted forms of the concentrated compositions, which can be used to provide a benefit to the skin of the user.
Systems, methods, and instrumentalities are described herein for identifying a user (e.g., a consumer) at risk for premature aging through dynamic facial imaging assessment. For example, a computing system may receive video data. The video data may be, or may include, one or more frames associated with the face of the user. The computing device may identify a frame from the video data. The computing device may determine a number of baseline wrinkles associated with the first state. The computing device may determine a number of dissipating wrinkles associated with the second state (e.g., a duration after the peak and relaxation of facial expression). Based on the number of baseline wrinkles and the number of dissipating wrinkles, the computing device may calculate a number of residual wrinkles between the first state and the second state. The computing device may map the number of residual wrinkles to the consumer risk for premature aging.
Systems, methods, and instrumentalities are described herein for identifying a user (e.g., a consumer) at risk for premature aging through dynamic facial imaging assessment. For example, a computing system may receive video data. The video data may be, or may include, one or more frames associated with the face of the user. The computing device may identify a frame from the video data. The computing device may determine a number of baseline wrinkles associated with the first state. The computing device may determine a number of dissipating wrinkles associated with the second state (e.g., a duration after the peak and relaxation of facial expression). Based on the number of baseline wrinkles and the number of dissipating wrinkles, the computing device may calculate a number of residual wrinkles between the first state and the second state. The computing device may map the number of residual wrinkles to the consumer risk for premature aging.
Methods for non-invasive or minimally invasive assessment of epithelial tissue structure are disclosed. Digital imaging and processing are used to identify cell locations. More specifically, an automated algorithm that may be used to identify epithelial tissue structure, and/or to specify the coordinates/locations of cells in the epithelial tissue structure, through non-invasive or minimally invasive imaging, and use of this information to extract values of epithelial structure related parameters are disclosed.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Provided are skincare compositions suitable for moisturizing the skin, and particularly compositions comprising relatively high amounts of glycerin. Exemplary skincare compositions may comprise: a. greater than 40% of one or more humectants by total weight of the composition; b. a mixture of esters of glycerin; c. one or more emollients; d. one or more skin conditioners; and e. water.
An adhesive bandage having a backing material and a hydrocolloid pad disposed thereon effectively removes wound exudate while enabling facile removal. The bandage includes a backing material comprising a sheet having an adhesive layer disposed thereon having a first color. The hydrocolloid pad has an absorbency (24 hr) of between about 2 and about 6 g/g, and includes a hydrocolloid layer forming a first surface thereof and a polymeric film layer having a second color associated therewith different than the first color of the backing material forming a second surface thereof. The hydrocolloid pad is disposed in facing relation and adhered to the adhesive layer of backing material. The first surface having a dry peel strength of between about 0 and about 650 gf/inch (255 gf/cm), a wet peel strength of between about 0 and 200 gf/inch (80 gf/cm).
A61F 13/0203 - Adhesive bandages or dressings with fluid retention members
A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
An adhesive bandage having a backing material and a hydrocolloid pad disposed thereon effectively removes wound exudate while enabling facile removal. The bandage includes a backing material comprising a sheet having an adhesive layer disposed thereon having a first color. The hydrocolloid pad has an absorbency (24 hr) of between about 2 and about 6 g/g, and includes a hydrocolloid layer forming a first surface thereof and a polymeric film layer having a second color associated therewith different than the first color of the backing material forming a second surface thereof. The hydrocolloid pad is disposed in facing relation and adhered to the adhesive layer of backing material. The first surface having a dry peel strength of between about 0 and about 650 gf/inch (255 gf/cm), a wet peel strength of between about 0 and 200 gf/inch (80 gf/cm).
A61F 13/0203 - Adhesive bandages or dressings with fluid retention members
A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
An adhesive bandage having a backing material and a hydrocolloid pad disposed thereon effectively removes wound exudate while enabling facile removal. The bandage includes a backing material comprising a sheet having an adhesive layer disposed thereon having a first color. The hydrocolloid pad has an absorbency (24 hr) of between about 2 and about 6 g/g, and includes a hydrocolloid layer forming a first surface thereof and a polymeric film layer having a second color associated therewith different than the first color of the backing material forming a second surface thereof. The hydrocolloid pad is disposed in facing relation and adhered to the adhesive layer of backing material. The first surface having a dry peel strength of between about 0 and about 700 gf, a wet peel strength of between about 0 and 150 gf.
A61F 13/0206 - Adhesive bandages or dressings with fluid retention members with absorbent fibrous layers, e.g. woven or non-woven absorbent pads or island dressings
Systems and methods for augmenting formulation design. The method includes determining a functional ingredient category for an individual ingredient in a requested new formulation; identifying a representative molecular structure of the individual ingredient in the determined functional ingredient category; generating, by a trained machine learning (ML) model, a predicted set of desired properties of i) the requested new formulation and ii) the identified representative molecular structure of the individual ingredient in the determined functional ingredient category; and generating, based on the generated predicted set of desired properties, a recommended predicted formulation that includes the identified representative molecular structure corresponding to the set of desired properties of the requested new formulation.
G06F 30/27 - Design optimisation, verification or simulation using machine learning, e.g. artificial intelligence, neural networks, support vector machines [SVM] or training a model
16.
SYSTEMS AND METHODS FOR AUGMENTING FORMULATION DESIGN
Systems and methods for augmenting formulation design. The method includes determining a functional ingredient category for an individual ingredient in a requested new formulation; identifying a representative molecular structure of the individual ingredient in the determined functional ingredient category; generating, by a trained machine learning (ML) model, a predicted set of desired properties of i) the requested new formulation and ii) the identified representative molecular structure of the individual ingredient in the determined functional ingredient category; and generating, based on the generated predicted set of desired properties, a recommended predicted formulation that includes the identified representative molecular structure corresponding to the set of desired properties of the requested new formulation.
G16C 60/00 - Computational materials science, i.e. ICT specially adapted for investigating the physical or chemical properties of materials or phenomena associated with their design, synthesis, processing, characterisation or utilisation
A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
G16C 20/70 - Machine learning, data mining or chemometrics
Solid cleansing compositions including at least a first surfactant and a second surfactant in which the combined weight of the first surfactant and the second surfactant is at least about 60% by weight, based on the total weight of the solid cleansing composition. The solid cleansing composition can be in a powder form.
Described are solid anhydrous formulations suitable for lip care comprising: greater than 40% to less than 60% of an oil mixture comprising at least 70% of C8-10 fatty acids; greater than 15% to less than 25% of a wax mixture comprising at least 20% of esters of C20-24 fatty acids with glycerol; and greater than 20% to less than 40% of at least one butter, wherein the at least one butter comprises a natural butter which is solid at 20° C. and has a melting point below 50° C., wherein all % are expressed in weight %.
A system, or kit, for hair care comprising a cleansing formulation and a hair conditioning formulation. The system includes a hair cleansing formulation comprising a surfactant mixture comprising at least an amphoteric surfactant, an anionic surfactant, and a non-ionic surfactant; and water. Active materials present in the surfactant mixture amount for at least 10%, in weight %, of the hair cleansing formulation. The system further includes a hair conditioning formulation comprising a conditioning agent, an emollient, and a non-ionic surfactant.
A skin-moisturizing composition includes at least two processed oat ingredients selected from Avena sativa kernel flour, Avena sativa kernel extract, and Avena sativa kernel oil; portulaca oleracea extract; and Limnanthes alba seed oil. A method of treating skin includes applying the skin-moisturization composition to the skin.
A hair cleansing formulation and method of manufacturing the same. The hair cleansing formulation comprises a surfactant mixture, wherein the surfactant mixture comprises at least: an amphoteric surfactant, an anionic surfactant, and a non ionic surfactant; a superhydrophilic amphiphilic copolymer that includes a starch-based polysaccharide derived from potato or tapioca modified with dodecenyl succinic anhydride; at least one cationic polymer, and water. The active materials present in the surfactant mixture amount for at least 10%, in weight %, of the hair cleansing formulation.
A hair cleansing formulation and method of manufacturing the same. The hair cleansing formulation comprises a surfactant mixture, wherein the surfactant mixture comprises at least: an amphoteric surfactant, an anionic surfactant, and a non ionic surfactant; a superhydrophilic amphiphilic copolymer that includes a starch-based polysaccharide derived from potato or tapioca modified with dodecenyl succinic anhydride; at least one cationic polymer; and water. The active materials present in the surfactant mixture amount for at least 10%, in weight %, of the hair cleansing formulation.
A system, or kit, for hair care comprising a cleansing formulation and a hair conditioning formulation. The system includes a hair cleansing formulation comprising a surfactant mixture comprising at least an amphoteric surfactant, an anionic surfactant, and a non-ionic surfactant; and water. Active materials present in the surfactant mixture amount for at least 10%, in weight %, of the hair cleansing formulation. The system further includes a hair conditioning formulation comprising a conditioning agent, an emollient, and a non-ionic surfactant.
A dispensing apparatus can be configured for dispensing material fluid from a container. The dispensing apparatus can include a collar, a fluid chamber, an actuator, and an air chamber. The collar can be configured to couple to a container defining a cavity configured to hold material. The fluid chamber can be fluid chamber coupled to the collar and configured to receive material from the cavity. The actuator can be movable relative to the collar from a first position to a second position. The actuator can be in fluid communication with the fluid chamber such that the actuator dispenses material from the fluid chamber as the actuator moves from the first position to the second position. The air chamber can be configured to urge the actuator from the second position to the first position.
B05B 11/00 - Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
B05B 11/10 - Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
Systems and methods for monitoring mold lifecycle and performance. The system includes a memory and a processor that receives, from a sensor implemented on a mold, first information associated with the mold, generates a digital molding process fingerprint associated with the mold based on the received first information, stores, in the memory, the generated digital molding process fingerprint, receives, from the sensor, second information associated with the mold, compares the received first information to the generated digital molding process fingerprint associated with the mold, and based on the comparison indicating a change in state of the mold, triggers a recommended action for the mold.
G05B 13/04 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric involving the use of models or simulators
B29C 37/00 - Component parts, details, accessories or auxiliary operations, not covered by group or
A computer system directed to digestive health, for example to diarrhea, can help direct a user to content specifically related to her experience, without requiring traditional user-entered search terms. Such a computer system may receive user-specific, timeseries data indicative of user- recorded diet, mood, and diarrhea symptoms. The computer system may capture this data in a smart phone daily diary application. The computer system may use this data to determine a correlation between the user-recorded diet and mood information and the user-recorded diarrhea symptom information. Then, an appropriate unit of content may be selected from a plurality of content units, such as from a database of digestive health information, based on the determined correlation. The selected unit can be presented to the user.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
32.
Correlation-Driven Search Information System For Digestive Health
A computer system directed to digestive health, for example to diarrhea, can help direct a user to content specifically related to her experience, without requiring traditional user-entered search terms. Such a computer system may receive user-specific, timeseries data indicative of user-recorded diet, mood, and diarrhea symptoms. The computer system may capture this data in a smart phone daily diary application. The computer system may use this data to determine a correlation between the user-recorded diet and mood information and the user-recorded diarrhea symptom information. Then, an appropriate unit of content may be selected from a plurality of content units, such as from a database of digestive health information, based on the determined correlation. The selected unit can be presented to the user.
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
Systems and methods for assessing enterprise-level risk assessment of a supplier. The method includes receiving an indication of a supplier; generating an impact score for the supplier; generating a likelihood score for the supplier; generating a combined risk score based on the generated impact score and the generated likelihood score; evaluating the generated combined risk score relative to a dynamic risk threshold; and based on the evaluation, generating an output including the generated combined risk score.
Systems and methods for assessing enterprise-level risk assessment of a supplier. The method includes receiving an indication of a supplier, generating an impact score for the supplier; generating a likelihood score for the supplier; generating a combined risk score based on the generated impact score and the generated likelihood score; evaluating the generated combined risk score relative to a dynamic risk threshold; and based on the evaluation, generating an output including the generated combined risk score.
The invention relates to composition for skin care. In particular the invention relates to skincare composition comprising a myrrh resin extract, and a processed oat ingredient. The invention also relates to a method of treating the skin using said composition, and to a method for activating lipid production in the skin layers.
A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
The invention relates to composition for skin care. In particular the invention relates to skincare composition comprising a myrrh resin extract, and a retinoid. The invention also relates to a method of treating the skin using said composition, and to a method for boosting the anti-aging effects of retinoids in the skin layers.
The invention relates to composition for skin care. In particular the invention relates to skincare composition comprising a myrrh resin extract, and a retinoid. The invention also relates to a method of treating the skin using said composition, and to a method for boosting the anti-aging effects of retinoids in the skin layers.
The invention relates to composition for skin care. In particular the invention relates to skincare composition comprising a myrrh resin extract, and a processed oat ingredient. The invention also relates to a method of treating the skin using said composition, and to a method for activating lipid production in the skin layers.
An improved notch-forming tab enables a blister card package comprising a medicament to be easily opened by a user. The blister card package includes a container sheet having a well formed therein; a cover sheet laminated to the container sheet and spanning the well to form a blister containing the medicament between the cover sheet and the container sheet; and a plurality of slits defining a pattern comprising a pair of legs having respective converging and diverging ends disposed adjacent the blister. The converging ends of the pair of legs are separated from one another by between about 0.1 mm and about 1 mm and are spaced from the blister. The diverging ends of the pair of legs are spaced from an adjacent edge of the blister pack. Methods of opening this and other inventive blister card packages are also described herein.
B65D 75/32 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
An improved notch-forming tab enables a blister card package comprising a medicament to be easily opened by a user. The blister card package includes a container sheet having a well formed therein; a cover sheet laminated to the container sheet and spanning the well to form a blister containing the medicament between the cover sheet and the container sheet; and a plurality of slits defining a pattern comprising a pair of legs having respective converging and diverging ends disposed adjacent the blister. The converging ends of the pair of legs are separated from one another by between about 0.1 mm and about 1 mm and are spaced from the blister. The diverging ends of the pair of legs are spaced from an adjacent edge of the blister pack. Methods of opening this and other inventive blister card packages are also described herein.
B65D 75/32 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
42.
METHOD FOR EVALUATING HOMOGENEITY OF ORAL SUSPENSIONS
A method for evaluating homogeneity of a suspension containing an active agent, including the steps of obtaining a test sample of the suspension in a container; subjecting the container to shaking at a shaker speed and for a duration of shaking; removing an aliquot of the suspension from the container; measuring the amount of the active agent in the aliquot; and comparing the amount of the active agent in the aliquot to an acceptance criteria. In one example, the suspension is a pharmaceutical suspension and the active agent is substantially insoluble.
A method for evaluating homogeneity of a suspension containing an active agent, including the steps of obtaining a test sample of the suspension in a container 1; subjecting the container to shaking at a shaker speed and for a duration of shaking; removing an aliquot of the suspension from the container; measuring the amount of the active agent in the aliquot; and comparing the amount of the active agent in the aliquot to an acceptance criteria. In one example, the suspension is a pharmaceutical suspension and the active agent is substantially insoluble.
B01F 31/24 - Mixing the contents of independent containers, e.g. test tubes the containers being submitted to a rectilinear movement
B01F 31/25 - Mixing the contents of independent containers, e.g. test tubes the containers being submitted to a combination of movements other than within a horizontal plane, e.g. rectilinear and pivoting movement
Systems and methods for generating a personal profile and a recommendation based on the generated personal profile. The method includes generating a plurality of clusters, each cluster of the generated plurality of clusters including at least a set of variables for users included in the cluster, the set of variables related to at least one of gender, age, skin tone, acne marks, acne frequency, a lesion score, or a body distribution score, generating, for a new user, a profile, associating the generated profile into a cluster of the plurality of clusters, and generating, by a machine learning (ML) model, a recommendation for the user based on the associated cluster.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
46.
PERSONAL PROFILE GENERATOR AND RECOMMENDATION ENGINE
Systems and methods for generating a personal profile and a recommendation based on the generated personal profile. The method includes generating a plurality of clusters, each cluster of the generated plurality of clusters including at least a set of variables for users included in the cluster, the set of variables related to at least one of gender, age, skin tone, acne marks, acne frequency, a lesion score, or a body distribution score, generating, for a new user, a profile, associating the generated profile into a cluster of the plurality of clusters, and generating, by a machine learning (ML) model, a recommendation for the user based on the associated cluster.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
47.
Personal Profile Generator and Recommendation Engine
Systems and methods for generating a personal profile and a recommendation based on the generated personal profile. The method includes generating a plurality of clusters, each cluster of the generated plurality of clusters including at least a set of variables for users included in the cluster, the set of variables related to at least one of gender, age, skin tone, acne marks, acne frequency, a lesion score, or a body distribution score, generating, for a new user, a profile, associating the generated profile into a cluster of the plurality of clusters, and generating, by a machine learning (ML) model, a recommendation for the user based on the associated cluster.
G06V 10/762 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using clustering, e.g. of similar faces in social networks
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
48.
PERSONAL PROFILE GENERATOR AND RECOMMENDATION ENGINE
Systems and methods for generating a personal profile and a recommendation based on the generated personal profile. The method includes generating a plurality of clusters, each cluster of the generated plurality of clusters including at least a set of variables for users included in the cluster, the set of variables related to at least one of gender, age, skin tone, acne marks, acne frequency, a lesion score, or a body distribution score, generating, for a new user, a profile, associating the generated profile into a cluster of the plurality of clusters, and generating, by a machine learning (ML) model, a recommendation for the user based on the associated cluster.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
49.
IN VITRO PRECLINICAL MODEL FOR CLINICAL IRRITATION AND SKIN BARRIER IMPAIRMENT POTENTIAL OF MILD SURFACTANT-BASED SKIN CLEANSING COMPOSITIONS
in vitroin vitro methods for predicting an in vivo clinical irritation marker of skin cleansing compositions and for predicting a skin barrier impairment potential property of skin cleansing compositions.
A reusable undergarment includes an undergarment fabric comprising a continuous waistband and front and back portions extending therefrom a crotch assembly. The crotch assembly includes a fabric topsheet, a barrier sheet, and at least one absorbent layer therebetween. The fabric topsheet has an outer, body-facing surface and an inner surface directed toward a barrier sheet. The outer, body-facing surface may a fibrous material and the inner surface comprises a hydrophobic fibrous material. The barrier sheet is impervious to liquids to prevent leakage therethrough. The at least one absorbent layer has a front edge, a back edge, and two side edges and a perimeter, the at least one absorbent layer being disposed between the fabric topsheet and the barrier sheet. At least a first hydrophobic treatment may be disposed about the perimeter of the at least one absorbent layer at least along the two side edges to inhibit fluid flow to the side edges of the at least one absorbent layer. The crotch assembly has an absorbent capacity of at least about 20 grams, a rate of absorption of at least about 0.1 mL/second, and a rewet % of less than about 20%.
A61F 13/49 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the bodySupporting or fastening means thereforTampon applicators characterised by the shape specially adapted to be worn around the waist, e.g. diapers, nappies
53.
Combination Method For Treating Or Preventing Childhood Atopic Disease
The present application describes methods of treating or reducing the onset or occurrence of childhood atopic disease. In particular, it relates to an integrated solution that accounts for temporal and sequential administrations of three different and specific approaches for optimal effectiveness in treating or reducing the onset or occurrence of childhood atopic disease.
Provided are compositions suitable for skin care. Certain compositions comprise
a. one or more a C20-24 fatty alcohols;
b. one or more anionic surfactants;
c. one or more thickening polysaccharides comprising succinoglycan;
d. one or more emollients comprising at least one natural butter having a natural butter which is solid at 20° C. and has a melting point below 50° C.; and
e. about 50 to about 95 wt. % of water by weight of the total composition, wherein the composition is in the form of an emulsion.
The present invention provides a topical composition including a topical analgesic, a viscosity increasing agent, a humectant, an emollient, and an emulsifier. The topical composition is substantially free of volatile alcohol. Additionally, the present invention includes methods of relieving pain. The methods include topically applying to an exterior skin portion of the user's body in need of pain treatment a composition including a topical analgesic, a viscosity increasing agent, a humectant, an emollient, and an emulsifier.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
The present invention provides a topical composition including a topical analgesic, a viscosity increasing agent, a humectant, an emollient, and an emulsifier. The topical composition is substantially free of volatile alcohol. Additionally, the present invention includes methods of relieving pain. The methods include topically applying to an exterior skin portion of the user's body in need of pain treatment a composition including a topical analgesic, a viscosity increasing agent, a humectant, an emollient, and an emulsifier.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
Provided are skincare compositions comprising (a) an emollient; (b) an occlusive; (c) a humectant; (d) a processed oat ingredient; (e) a rheological modifier; and (f) water. Also provided are method of using and processing said compositions.
Provided are methods of treating skin using skincare compositions comprising (a) an emollient; (b) an occlusive; (c) a humectant; (d) a processed oat ingredient; (e) a rheological modifier; and (f) water.
Provided are methods of quantifying miRNA in skin, the method comprising: applying a swellable microprotrusion array to a region of skin to absorb interstitial fluid; removing the microprotrusion array; recovering miRNA from the interstitial fluid absorbed into the microprotrusion array; and quantifying the miRNA. Also provided are methods of monitoring epigenetic changes in skin using a swellable microprotrusion array.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present invention provides a sunscreen composition comprising: (a) diethylamino hydroxybenzoyl hexyl benzoate; (b) bis-ethylhexyloxyphenol methoxyphenyl triazine; (c) ethylhexyl triazone; and (d) methylene bis-benzotriazolyl tetramethylbutylphenol; wherein the sunscreen composition is substantially free of UV absorbers having a molecular mass of 380 Daltons or less.
The present invention provides a sunscreen composition comprising: (a) diethylamino hydroxybenzoyl hexyl benzoate; (b) bis-ethylhexyloxyphenol methoxyphenyl triazine; (c) ethylhexyl triazone; and (d) methylene bis-benzotriazolyl tetramethylbutylphenol; wherein the sunscreen composition is substantially free of UV absorbers having a molecular mass of 380 Daltons or less.
Sulfate-free cleansing compositions that include a surfactant and a conditioning agent are disclosed. The cleansing compositions are suitably thick and have a desired level of clarity. The cleansing compositions, which are slightly acidic, are mild to the skin and/or eyes.
The present invention relates to advanced methods of treating a wound comprising the steps of cleansing the wound with an antiseptic formulation, applying an antibiotic formulation to the wound, covering the wound with an adhesive bandage, and repeating these steps for at least two additional, consecutive days.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
The present invention provides an anhydrous sunscreen composition comprising: (a) at least about 15% by weight based on the total weight of the sunscreen composition of a combination of titanium dioxide and zinc oxide, wherein the weight ratio of zinc oxide to titanium dioxide in the composition is about 0.5 to about 1.5; (b) at least about 50% by weight based on the total weight of the sunscreen composition of a carrier oil, wherein the carrier oil comprises at least 50% by weight Helianthus Annuus (Sunflower) Seed Oil; (c) about 10% to about 20% by weight based on the total weight of the sunscreen composition a combination of Isododecane and Diisopropyl Adipate; and (d) about 2% to about 6% by weight based on the total weight of the sunscreen composition of a film former comprising triacontanyl PVP.
Methods of screening types and amounts of antioxidants, determining effectiveness of the antioxidants, preparing compositions including effective amounts of the antioxidants (and uses thereof), and reducing the formation of clogged pores and acne are provided. Methods include the formation of test samples in a solvent system (optionally with one or more bacterial metabolites) including one or more antioxidants in amounts to be evaluated for effectiveness against control samples without antioxidants. The samples are exposed to an oxidation-inducing element (such as UVA rays) and the amount of oxidation byproduct is evaluated. Based on the effectiveness of the antioxidant(s) in the amount(s) tested, formulations can be prepared to include the one or more antioxidants in the amount(s) effective to reduce oxidation of the oxidizable component, preventing and reducing the formation of the oxidation byproduct. The formulations can be used, for example, to reduce the formation of clogged pores and acne.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
A61K 9/00 - Medicinal preparations characterised by special physical form
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
72.
System and method for selective application of cosmetic composition to impart undereye brightening
A device and method for selectively applying a composition to a treatment surface (e.g., skin) to alter an aesthetic appearance of the skin in the undereye region of the face. The device includes an applicator applying the composition to the skin, and a detector obtaining image data corresponding to an image of an area of skin. The device generates a target reflectance value based on the image data and past image data. The target reflectance value is higher than reflectance of at least half of areas corresponding to the image data and past image data. The device determines a desired level of reflectance modification for a location within the area of skin imaged by comparing image data corresponding to reflectance of the location to the target reflectance value, and directs the applicator to selectively apply the composition to the location based on the desired level of reflectance modification.
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
Provided are methods of acclimating skin to a retinoid, the method comprising: topically applying to the skin a first composition comprising a retinoid at a first concentration at a first frequency for a first period of time; topically applying to the skin the first composition at a second frequency for a second period of time; topically applying to the skin a second composition comprising a retinoid at a second concentration at a third frequency for a third period of time; and topically applying to the skin the second composition at a fourth frequency for a fourth period of time.
Provided are compositions methods of preventing, delaying or ameliorating atopic dermatitis in a breastfed infant having an increased risk of developing an atopic disease, the method comprising administering a composition comprising administering a Bifidobacterium to the breastfed infant.
A system and method of determining an allergy impact profile of an individual are disclosed. The system and method may be employed to predict allergy impact environmental conditions may have on allergy symptoms of an individual and to recommend treatment of the individual in response to the predicted allergy impact.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G01D 21/00 - Measuring or testing not otherwise provided for
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
78.
METHOD TO MITIGATE ALLERGEN SYMPTOMS IN A PERSONALIZED AND HYPERLOCAL MANNER
A system and method of determining an allergy impact profile of an individual are disclosed. The system and method may be employed to predict allergy impact environmental conditions may have on allergy symptoms of an individual and to recommend treatment of the individual in response to the predicted allergy impact.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G01D 21/00 - Measuring or testing not otherwise provided for
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
79.
Systems and Methods for Automatic Cell Identification Using Images of Human Epithelial Tissue Structure
Systems and methods for improving the image quality of images of epithelial tissue structures are disclosed. The systems include training a first cycle-GAN model and a second cycle-GAN model simultaneously, where the first cycle-GAN model is trained to remove noise from an image and the second cycle-GAN model is trained to learn the structure of the image. Additional systems and methods include deploying the trained cycle-GAN model to identify an unknown image segment and/or generate a protocol for following the identified skin care treatment recommendation for an identified image segment.
Provided are methods and compositions suitable for treating acne, disrupting a biofilm, and/or killing bacteria contained in a biofilm. Certain methods comprise contacting skin in need of such treatment with a composition comprising two alpha hydroxy acids and a polyhydroxy acid.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Provided are methods and compositions suitable for treating acne, disrupting a biofilm, and/or killing bacteria contained in a biofilm. Certain methods comprise applying to a surface having a biofilm a composition comprising a first alpha hydroxy acid, a second alpha hydroxy acid, and a polyhydroxy acid.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Biomimetic, prebiotic, probiotic and postbiotic compositions and methods of use thereof are disclosed. The biomimetic, prebiotic, probiotic and postbiotic compositions may include bacteria of the genera Cutibacterium acnes (C. acnes), its culture and/or components thereof; and/or a substance that induces the growth or activity of C. acnes. The biomimetic, prebiotic, probiotic and postbiotic compositions may be used in preventing, improving and/or treating such conditions such as atopic dermatitis.
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to a pharmaceutical liquid composition, wherein said liquid composition comprises at least one cooling agent comprising of a phenyl ring containing a polar side group at least one viscosity enhancing agent and at least one surfactant. The invention also relates to a method to produce such a pharmaceutical composition as well as a method of alleviating a symptom selected from the group consisting of cough, nasal congestion and sore throat in a subject comprising administering the composition according to any of preceding claims.
An absorbent article comprising a liquid permeable cover layer, an impervious barrier layer and an absorbent core between the cover layer and the barrier layer, wherein the barrier layer is impervious and biodegradable and comprises a kraft paper layer and a continuous resin coating; wherein the continuous resin coating is on the surface of the barrier layer disposed toward the absorbent core, and the continuous resin coating weight is from 10 to 18 g/m2, and the continuous resin coating is an acrylic copolymer.
A61F 13/514 - Backsheet, i.e. the impermeable cover or layer furthest from the skin
A61F 13/15 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the bodySupporting or fastening means thereforTampon applicators
A61F 13/47 - Sanitary towels, incontinence pads or napkins
Provided are methods of reducing pain or itch, the method comprising administering to a patient in need thereof a therapeutically effective dose of a composition comprising a non-polar extract of Iceland moss.
Provided are methods of determining effectiveness of face treatments comprising: providing a front-facing image of the face prior to use of the treatment; identifying a y-axis of the face, wherein the y-axis is defined by a line connecting the center position of the chin of the face through the center of the face; identifying an x-axis of the face, wherein the x-axis is defined by a line that is positioned at a 90-degree angle from the y-axis and goes through the center of the chin of the face; selecting a facial landmark; identifying a facial landmark line, wherein the facial landmark line is defined by a line connecting the center position of the chin of the face to the facial landmark; measuring the angle between the x-axis and the facial landmark line; carrying out the treatment on the face; providing a front-facing image of the face after the treatment.
The present application describes methods of treating or reducing the onset or occurrence of childhood atopic disease. In particular, it relates to an integrated solution that accounts for temporal and sequential administrations of three different and specific approaches for optimal effectiveness in treating or reducing the onset or occurrence of childhood atopic disease.
The invention relates to a coated famotidine particle having at least a core and a coating layer, wherein the particle core comprises famotidine, a first filler and a first binder; and wherein the coating layer is substantially free from famotidine and comprises a second filler and a second binder. The invention also relates to solid dosage forms comprising said coated famotidine particle, and the use of the coated famotidine particle for treating a subject suffering from a disease or disorder in the gastrointestinal tract.
Systems, methods, and instrumentalities may be configured for managing infant health. An example system may communicate with a user device to collect and assess infant health metrics and parental usage. The system may configure a health trajectory for the infant by analyzing parental compliance and aggregate health data for generating an intervention data set. Interventions may be sent to the user device based on projected benefits and encouraging parental action. Health metrics may modify the health trajectory and interventions based on the infant's development and parental engagement. The system may monitor user compliance such that interventions are presented to maximize completion likelihood.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
99.
Systems, Methods, Mediums, and Apparatuses for Capturing Medications and Medication Usage
Systems, methods, non-transitory computer-readable mediums, and/or apparatuses are provided for determining a medication used by a patient. Label information for a medication may be determined. A source national drug code (NDC) associated with the medication may be determined. The source NDC may be validated. A product NDC and a normalized identifier may be determined. A brand name associated with the medication may be determined. One or more active ingredients associated with the brand name may be determined. A drug display name may be determined. The drug display name and active ingredient information for the one or more active ingredients may be displayed. A summary indicating an amount of the active ingredient may be displayed, for example, based on a medication diary.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
100.
TOPICAL COMPOSITIONS CONTAINING N-ACYL DIPEPTIDE DERIVATIVES AND GLYCOLIC ACID
The present invention provides topical compositions comprising a combination of an N-acyl dipeptide derivative and glycolic acid. The compositions provide enhanced penetration of the N-acyl dipeptide derivative into the skin.
patents
